EGFR/ERBB1/HER1 and ERBB2/EGFR2/HER2 are members of the ErbB super family of receptor tyrosine kinases. These receptors bind multiple EGF family-member ligands to initiate signaling cascades critical for an array of cellular processes, such as proliferation, differentiation, survival, metabolism, and migration. EGFR and ERBB2 are targets of an expanding class of anticancer therapies. The most common mutations associated with sensitivity to EGFR inhibitors include exon 19 deletions and the L858R point mutation. Conversely, the EGFR T790M Mutation has been linked to drug resistance.
The EGFR genetic alteration cell panel (ATCC TCP-1027) is composed of eleven human tumor cell lines from various common cancer types that carry hotspot mutations or gene copy number amplification within the EGFR or ERBB2 gene. The EGFR and ERBB2 status of each cell line has been sequenced and validated by ATCC. This panel is useful for EGFR pathway research and for anti-cancer drug discovery.